The Vision and Eye Research Institute (VERI), formerly VERU, offers a multi-disciplinary collaborative environment for all vision and eye research in Anglia Ruskin University by building on existing and new collaborative research links amongst the different departments and faculties.
It brings in research expertise across a wide range of specialities including optometry, ophthalmology, computing sciences, human movement sciences, sports sciences, biomedical sciences, psychology, hearing sciences and business.
VERI acts as a focus for research and development, uniting leading authorities in the field together with public and private sector stakeholders to create a platform where expertise and resources can be focused directly on some of the most pressing challenges facing the vision and eye. With the continued support of key partners, it is a challenge that VERI is well equipped to meet in terms of resources, infrastructure and expertise.
To carry out world class research in key research areas in vision and eye, developing the institute as a World Class Research platform, bringing together a multi-disciplinary team of experts and stakeholders with a common mission of delivering high class research to reduce the impact of global blindness.
Professor Shahina Pardhan is the Director of the VERI, based in the School of Medicine. Professor Pardhan was appointed as the first female Professor of Optometry in the UK (2001). She is supported by a multidisciplinary team.
VERI’s research submission to the 2014 Research Excellence Framework (REF2014) was rated as 100% world leading, internationally excellent and excellent. VERI research has shaped strategies and practices of international organisations and large charities.
VERI staff have won a number of awards, including:
VERI facilitates impact through our high-quality research with the aim of decreasing the risk of blindness and improving quality of life for those who are visually impaired.
The Vision Loss Expert Group (VLEG) data have informed strategies and practices for international organisations, countries and large charities. The WHO, UN and the governments of Australia, Sierra Leone and Nigeria have made eye-health policies and/or investment decisions based on the research findings. Charities in the UK, US and Australia, working across 20 countries, have used the data to underpin their lobbying activities and to inform their strategies and investment decisions.
Our research has highlighted the need for improved health literacy, lifestyle changes and retinal screening uptake in people of Asian origin in order to reduce the risk of diabetic retinopathy. This has led to a number of strategies/interventions in the UK (at grassroots levels), Nepal, China, India and Thailand, impacting patients with diabetes and healthcare professionals, leading to changed behaviour and improved patient outcomes.
VERI moved into purpose-built research centre (190 m2), with state-of -art- facilities in Cambridge in 2015, following a capital investment of £900,000 from ARU. Find out more about our research facilities.
Clinical research needs to be directed to improving evidence base, and VERI is well placed to define the key areas to be addressed and to set up the necessary controlled clinical trials.
By working closely with the optical and pharmaceutical industries as well as key NHS partners, VERI is in a unique position to understand the needs of patients, service providers and private sector companies. Visit our partners page for more information.
Vision and Eye Research Institute (VERI)
Anglia Ruskin University
Cambridge CB1 2LZ